α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus.
Qian LiDing WeiFei FengXi-Long WangCan LiZhi-Nan ChenHui-Jie BianPublished in: Journal of cancer research and clinical oncology (2017)
The study provides evidence of optimized therapeutic strategy in oncolytic virotherapy via partly defining α2,6-sialylated receptor as a "cellular marker" for NDV.